BR112013004917A2 - terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais. - Google Patents

terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.

Info

Publication number
BR112013004917A2
BR112013004917A2 BR112013004917A BR112013004917A BR112013004917A2 BR 112013004917 A2 BR112013004917 A2 BR 112013004917A2 BR 112013004917 A BR112013004917 A BR 112013004917A BR 112013004917 A BR112013004917 A BR 112013004917A BR 112013004917 A2 BR112013004917 A2 BR 112013004917A2
Authority
BR
Brazil
Prior art keywords
stem cell
tissue
animals
mesenchymal stem
treating diseases
Prior art date
Application number
BR112013004917A
Other languages
English (en)
Inventor
Erik John Woods
Shelly J Zacharias
Sreedhar Thirumala
Original Assignee
Cook General Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cook General Biotechnology Llc filed Critical Cook General Biotechnology Llc
Publication of BR112013004917A2 publication Critical patent/BR112013004917A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)

Abstract

terapias de célula tronco alogênica sistêmica para tratamento de doenças em animais. é descrito um método para tratar doenças pré-selecionadas compreendendo as etapas de fornecer uma dose terapêutica de uma composição de célula tronco mesenquimal, a composição de célula tronco mesenquinal compreendendo células tronco mesenquimais colhidas de pelo menos um tecido selecionado do grupo que consiste em tecido placentário, medula óssea, tecido dentário, tecido testicular, e tecido dérmico; e administrar sistemicamente a composição de célula tronco mesenquimal ao paciente que sofre de umadoença ou estado enfermo pré-selecionado através de uma injeção intravenosa.
BR112013004917A 2010-08-31 2011-08-31 terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais. BR112013004917A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37845710P 2010-08-31 2010-08-31
PCT/US2011/049977 WO2012030968A1 (en) 2010-08-31 2011-08-31 Systemic, allogenic stem cell therapies for treatment of diseases in animals

Publications (1)

Publication Number Publication Date
BR112013004917A2 true BR112013004917A2 (pt) 2016-09-20

Family

ID=45697573

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013004917A BR112013004917A2 (pt) 2010-08-31 2011-08-31 terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.

Country Status (11)

Country Link
US (6) US20120052049A1 (pt)
EP (1) EP2611906B1 (pt)
JP (2) JP2013536860A (pt)
CN (1) CN103180435A (pt)
AU (1) AU2011295954B2 (pt)
BR (1) BR112013004917A2 (pt)
CA (1) CA2809272A1 (pt)
DK (1) DK2611906T3 (pt)
PL (1) PL2611906T3 (pt)
PT (1) PT2611906T (pt)
WO (1) WO2012030968A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453202B2 (en) 2003-10-08 2016-09-27 Vet-Stem, Inc. Methods of preparing and using novel stem cell compositions and kits comprising the same
EP2624845A4 (en) 2010-10-08 2015-09-09 Mesoblast Internat S Rl REINFORCED MSC PREPARATIONS
AU2013380203B2 (en) 2013-02-27 2017-04-06 Med Invent Devices Private Limited Device providing enlargement & preventing collapse of the pupil of the eye
US20140314872A1 (en) * 2013-04-22 2014-10-23 Hans Klingemann Methods of Use of Culture Supernatant Obtained from Mesenchymal Stem Cells from Dogs and Cats for Treatment of Organ Dysfunction
WO2015023901A1 (en) * 2013-08-15 2015-02-19 The Regents Of The University Of California Placenta-derived multipotent stem cells
KR102313054B1 (ko) 2013-08-27 2021-10-18 쿡 제너럴 바이오테크놀로지 엘엘씨 혈소판 농축물로부터 유도될 수 있는 생물활성 조성물, 및 이를 제조하는 방법 및 사용 방법
EA024138B1 (ru) * 2013-10-17 2016-08-31 Акционерное Общество "Научный Центр Урологии Имени Академика Б.У. Джарбусынова" Способ проведения клеточной терапии для лечения экспериментального хронического орхоэпидидимита
EA025096B1 (ru) * 2013-10-17 2016-11-30 Акционерное Общество "Научный Центр Урологии Имени Академика Б.У. Джарбусынова" Способ проведения клеточной терапии для лечения экспериментального хронического орхоэпидидимита
US10801014B2 (en) * 2013-12-06 2020-10-13 Global Stem Cell Technology Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells
DK3083944T3 (da) * 2013-12-19 2021-02-15 Univ Liege Pattedyrsmuskelafledte stamceller
US20150216539A1 (en) * 2014-02-06 2015-08-06 Stryker European Holdings I, Llc Bone marrow harvesting and storage
WO2016015007A1 (en) * 2014-07-25 2016-01-28 Recellerate, Inc. Methods of treating exercise-induced pulmonary hemorrhage
CA2962239C (en) * 2014-09-29 2024-01-02 Cook General Biotechnology Llc Uses of trehalose in cell suspensions
MA40996A (fr) * 2014-11-17 2017-09-26 Univ Miami Matériaux et procédés de traitement d'un dysfonctionnement endothélial et procédés de surveillance de l'efficacité du traitement chez un patient
CN114224916A (zh) * 2014-12-23 2022-03-25 迈索布拉斯特国际有限公司 用于治疗心力衰竭的方法
US10342830B2 (en) 2015-01-05 2019-07-09 Gary M. Petrucci Methods and materials for treating lung disorders
EP3273881B1 (en) 2015-03-24 2019-10-09 Stryker European Holdings I, LLC Bone marrow harvesting device
WO2017022628A1 (ja) * 2015-07-31 2017-02-09 国立大学法人大阪大学 上皮疾患に対する治療及び／又は予防有効性を評価する方法、上皮疾患治療剤のスクリーニング方法、及び上皮疾患治療剤
AU2016321448B2 (en) * 2015-09-08 2023-02-02 Cell Ideas Pty Ltd Cell expansion methods and therapeutic compositions
US11149249B2 (en) * 2015-09-25 2021-10-19 Mitsubishi Gas Chemical Company, Inc. Base material for cell culture and cell culture method using same, cell culture container, and use as base material
CN106085954A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 一种大量人外周血pbmc快速分离方法
CN106265744A (zh) * 2016-09-29 2017-01-04 广州赛莱拉干细胞科技股份有限公司 脐带间充质干细胞在制备治疗角膜损伤的干细胞制剂中的应用
CA3043594A1 (en) * 2016-11-11 2018-05-17 Longeveron Llc Methods of using human mesenchymal stem cells to effect cellular and humoral immunity
US10478531B2 (en) 2017-06-22 2019-11-19 Gary M. Petrucci Methods and materials for treating blood vessels
US10251917B1 (en) 2017-09-19 2019-04-09 Gary M. Petrucci Methods and materials for treating tumors
FI3752598T3 (fi) * 2018-02-16 2023-02-22 Allogeeninen koostumus
MA52883A (fr) * 2018-06-15 2021-05-26 Prieto Manuel Hermida Composition pharmaceutique pour dermatologie et ses utilisations
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
CN109370986A (zh) * 2018-12-11 2019-02-22 南京农业大学 一种犬脂肪干细胞的提取方法及其制剂和应用
WO2020144382A2 (fr) * 2019-01-11 2020-07-16 Vetbiobank Cellules stromales neonatales felines et leurs utilisations
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
CN112941021A (zh) * 2020-03-13 2021-06-11 深圳市第二人民医院(深圳市转化医学研究院) 一种骨关节炎关节液来源的间充质干细胞的培养方法
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health Inc PERMEATION OF WHOLE VERTEBRAL BODY WITH CRYOPROTECTIVE USING VACUUM-ASSISTED DIFFUSION
CA3195653A1 (en) 2020-10-14 2022-04-21 Ossium Health, Inc. Systems and methods for extraction and cryopreservation of bone marrow
CN117279650A (zh) 2020-12-18 2023-12-22 奥瑟姆健康公司 细胞治疗方法
AU2022209856A1 (en) * 2021-01-19 2023-08-17 Gallant Pet, Inc. Methods for optimizing reproductive tissue derived cell yield and viability for clinical applications
CN117460517A (zh) * 2021-05-21 2024-01-26 株式会社大熊制药 用于预防或治疗犬科动物糖尿病的含有依那格列净的药物组合物
TW202319059A (zh) * 2021-07-08 2023-05-16 比利時商比利時百靈佳殷格翰動物醫藥公司 用於治療動物之骨關節炎之間葉幹細胞

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5550127A (en) * 1995-09-07 1996-08-27 Pantano; James A. Method of treatment for eiph in racing stock
EP1062321B1 (en) * 1998-03-13 2004-12-29 Osiris Therapeutics, Inc. Uses for humane non-autologous mesenchymal stem cells
DE60143517D1 (de) * 2000-04-25 2011-01-05 Osiris Therapeutics Inc Wiederherstellung der gelenken mit mesenchymalen stammzellen
EP2263698A1 (en) * 2003-04-01 2010-12-22 United States of America Dempartment of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
PL2338982T3 (pl) * 2003-06-27 2016-01-29 Depuy Synthes Products Inc Komórki poporodowe pochodzące z tkanek pępowinowych i sposoby ich wytwarzania i zastosowania
KR20050044849A (ko) * 2003-11-07 2005-05-13 학교법인 인하학원 중간엽 줄기세포로부터 연골세포를 분화시키는 방법
EP2298862B1 (en) * 2004-03-22 2017-08-30 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
CN1676603A (zh) * 2004-03-30 2005-10-05 中国人民解放军军事医学科学院基础医学研究所 一种人骨髓间充质干细胞体外扩增的新方法
JP2006078034A (ja) * 2004-09-08 2006-03-23 Ntt Power & Building Facilities Inc 室外機及び室外機の設置方法
JP2006123699A (ja) * 2004-10-28 2006-05-18 Miyata Ind Co Ltd 樹脂製自転車フレーム又はその部品、及びそれらの製造方法
WO2006088867A2 (en) * 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
JP2008544957A (ja) * 2005-05-10 2008-12-11 ユナイテッド ステイツ オブ アメリカ デパートメント オブ ヴェテランズ アフェアーズ 間充織幹細胞による腎疾患及び多臓器不全の治療法と間充織幹細胞馴化培地
CN100344757C (zh) * 2005-10-18 2007-10-24 天津昂赛细胞基因工程有限公司 人胎盘、脐带间充质干细胞库及其构建方法
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
DK2626417T3 (en) * 2006-03-23 2015-11-02 Pluristem Ltd Methods for cell expansion and use of the thus produced cells and conditioned media for the therapy
US7724211B2 (en) * 2006-03-29 2010-05-25 Nvidia Corporation System, method, and computer program product for controlling stereo glasses shutters
KR20090043559A (ko) * 2006-08-15 2009-05-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 중간엽 줄기세포 조절배지
US7947435B2 (en) * 2007-01-19 2011-05-24 Seoul National University Industry Foundation Neuronal regeneration material screening method by ex vivo model
JP4926872B2 (ja) * 2007-07-27 2012-05-09 シャープ株式会社 イオン発生素子の製造方法、イオン発生素子、帯電装置および画像形成装置
US20110262402A1 (en) * 2007-09-07 2011-10-27 Masahiko Kuroda Therapeutic and prophylactic agents for arthritis
US20090214484A1 (en) * 2008-02-22 2009-08-27 Nikolay Mironov Stem cell therapy for the treatment of central nervous system disorders
US8318485B2 (en) * 2008-02-25 2012-11-27 Natalie Gavrilova Stem cell therapy for the treatment of diabetic retinopathy and diabetic optic neuropathy
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
US20130164267A1 (en) * 2008-06-11 2013-06-27 Cell4Vet Corporation Adipose tissue-derived stem cells for veterinary use
EP2186883A1 (en) * 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
US20110305673A1 (en) * 2008-11-12 2011-12-15 The University Of Vermont And State Agriculture College Compositions and methods for tissue repair
BRPI0921414A2 (pt) * 2008-11-20 2019-09-24 Manuel Diaz Arroyo população de células-tronco mesenquimais isoladas, composição farmacêutica, e, método para isolar uma população de células-tronco de tecido miometrial.
US20100297094A1 (en) * 2009-01-30 2010-11-25 Harlan John M Therapy or prevention of diseases with cells or cell supernatant
EP2446024A1 (en) * 2009-06-26 2012-05-02 Life&Light Limited Mesenchymal stem cells grown under hypoxic conditions: compositions, methods and uses therefor
US20120201791A1 (en) * 2009-10-15 2012-08-09 Tai June Yoo Methods of treating diseases or conditions using mesenchymal stem cells

Also Published As

Publication number Publication date
US20120269786A1 (en) 2012-10-25
EP2611906B1 (en) 2024-01-03
DK2611906T3 (da) 2024-04-08
CA2809272A1 (en) 2012-03-08
US20120269787A1 (en) 2012-10-25
EP2611906A4 (en) 2014-03-19
PT2611906T (pt) 2024-04-16
CN103180435A (zh) 2013-06-26
JP2013536860A (ja) 2013-09-26
EP2611906A1 (en) 2013-07-10
US20170014454A1 (en) 2017-01-19
US20120052049A1 (en) 2012-03-01
WO2012030968A1 (en) 2012-03-08
US20220096558A1 (en) 2022-03-31
AU2011295954A1 (en) 2013-04-11
JP2016185972A (ja) 2016-10-27
US20120269785A1 (en) 2012-10-25
AU2011295954B2 (en) 2015-08-13
PL2611906T3 (pl) 2024-05-27

Similar Documents

Publication Publication Date Title
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
WO2009089110A3 (en) Methods for repair and regeneration of bone marrow
ES2721180T3 (es) Productos terapéuticos usando células adiposas y secreciones celulares
BR112013002655A2 (pt) novo tratamento de carcinoma de próstata
NZ606825A (en) Methods and compositions for treating complement-associated disorders
TN2012000270A1 (en) Methods and low dose regimens for treating red blood cell disorders
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
WO2012071526A3 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
BR112012031163A2 (pt) métodos de terapia combinada para tratamento de doenças proliferativas
CR11724A (es) Agente para tratar enfermedades
WO2010082787A3 (ko) 연골줄기세포를 유효성분으로 포함하는 골질환 치료용 또는 항염증용 약제학적 조성물
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
EP3818991A3 (en) Compositions and methods for treating diseases
BRPI0919020A2 (pt) Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2013100818A3 (en) A biocomposite for regeneration of injured tissue and organs, a kit for making the biocomposite, a method of making the biocomposite and a method of treating inquiries.
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
WO2013126590A8 (en) Pharmaceutical composition comprising cd34+ cells
HK1205677A1 (en) Mesenchymal stem cells and uses therefor
MX358680B (es) Usos de inmunoconjugados dirigidos a cd138.
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]